Mostra i principali dati dell'item
Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA
dc.creator | Pavlidis, P. | en |
dc.creator | Shums, Z. | en |
dc.creator | Koutsoumpas, A. L. | en |
dc.creator | Milo, J. | en |
dc.creator | Papp, M. | en |
dc.creator | Umemura, T. | en |
dc.creator | Lakatos, P. L. | en |
dc.creator | Smyk, D. S. | en |
dc.creator | Bogdanos, D. P. | en |
dc.creator | Forbes, A. | en |
dc.creator | Norman, G. L. | en |
dc.date.accessioned | 2015-11-23T10:45:15Z | |
dc.date.available | 2015-11-23T10:45:15Z | |
dc.date.issued | 2015 | |
dc.identifier | 10.1016/j.cca.2014.12.010 | |
dc.identifier.issn | 0009-8981 | |
dc.identifier.uri | http://hdl.handle.net/11615/32110 | |
dc.description.abstract | Background: We developed a new IgA and IgG anti-MZGP2 antibody ELISAs based on recombinant isoform-4 of human zymogen granule protein-2 (GP2), which is the major autoantigen of Crohn's disease (CrD)-specific pancreatic autoantibodies and assessed their clinical relevance in the largest inflammatory bowel disease (IBD) cohort tested to date. Methods: 832 sera were studied, including 617 consecutive IBD patients from 323 CrD and 294 ulcerative colitis (UC) follow-up in a tertiary centre, and 112 pathological and 103 normal controls. Results: Sensitivity of IgA anti-MZGP2 for CrD in the IBD population was 15% and specificity was 98% (95, 99), while the sensitivity and specificity of IgG anti-MZGP2 were 27% and 97%. IgA and IgG anti-MZGP2 combined testing led to a sensitivity of 31% and a specificity of 96%. Positivity for either ASCA (IgA or IgG) or anti-MZGP2 (IgA or IgG) showed a sensitivity of 75% (70, 80) and a specificity of 84% (79, 89). IgA anti-MZGP2 antibodies were more prevalent in CrD patients with early disease onset (p = 0.011). Also, anti-MZGP2 positive patients more frequently had extensive disease with ileal involvement. Patients with longer disease duration were more likely to have IgG anti-MZGP2 antibodies. Conclusions: Our novel ELISA confirms the high specificity of anti-MZGP2 antibodies for CrD and their association with disease severity phenotypes. (C) 2014 Elsevier B.V. All rights reserved. | en |
dc.source.uri | <Go to ISI>://WOS:000350085300030 | |
dc.subject | Autoantibody | en |
dc.subject | Bowel disease | en |
dc.subject | Marker | en |
dc.subject | Sensitivity | en |
dc.subject | Specificity | en |
dc.subject | INFLAMMATORY-BOWEL-DISEASE | en |
dc.subject | AUTOANTIBODIES | en |
dc.subject | GLYCOPROTEIN | en |
dc.subject | CLASSIFICATION | en |
dc.subject | PATHOGENESIS | en |
dc.subject | GENETICS | en |
dc.subject | GP2 | en |
dc.subject | Medical Laboratory Technology | en |
dc.title | Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA | en |
dc.type | journalArticle | en |
Files in questo item
Files | Dimensione | Formato | Mostra |
---|---|---|---|
Nessun files in questo item. |